FIG. 1A

FIG. 1B

FIG. 1C




FIG. 2

FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

Table 1: Effects of Berberine and Catalpol on Plasma sugar levels of Mice

	Plasma Glucose Level after Injections				
Days	7	14	21	28	38
Berberine/catalpol (n=20)	90.21*	94.38*	82.47*	90.34*	97.21*
Control (n=12)	185.96	189.21	182.33	188.45	195.28

^{*} p<0.01

FIG. 12

Table 2: The effects of berberine and catalpol on Insulin beta Cell Count

	The count of various grade groups					
Group	Ineffective	Improved	Clearly Effective	Controlled	Total	Average
Control (n=12)	9	3	0	0	33	2.75
Berberine and catalpol (n=20)	0	2	5	13	15.5	0.775**

P<0.01

Table 4: The effects of berberine and catalpol (50mg/kg/dl) on plasma glucose level of normal mice (X±SD)

·	Plasma Glucose (mg/dl)	
	Control (no drug) Berberine and c	
		administration
One time administration	130.8 <u>+</u> 22.6 (n=10)	72.4 <u>+</u> 31.1 (n=10)*
Seven day administration	135.6 <u>+</u> 36.3 (n=9)	74.6 <u>+</u> 22.3 (n=9)*

^{*}p<0.01

FIG. 14

Table 5: Effects of berberine and catalpol on plasma glucose level elevation caused by adrenaline (10 mice in each group X ± SD)

Group	Dose (mg/kg)	Plasma glucose (mg/dl)
Saline only	Not applicable	167.4 <u>+</u> 18.5
Adrenaline only	0.02 iP	225.1 <u>+</u> 51.2
Adrenaline and berberine	002, iP & 50, PO	172.6 <u>+</u> 26.8*
and catalpol		

^{*}p<0.02

Table 6: Effect of berberine and catalpol (50 mg/kg/dl) on the plasma glucose level of the tetraoxide alloxan diabetic mice

	Plasma glucose le	Plasma glucose level (mg/dl)		
Day	Control	Berberine and catalpol		
1	295.3 <u>+</u> 72.2	153.2 <u>+</u> 81.2*		
5	531.8 <u>+</u> 84.5	320.2 <u>+</u> 96.3**		
10	478.2 <u>+</u> 61.4	150.6 <u>+</u> 56.5***		

^{*}p<0.01

FIG. 16

Table 7: Effect of berberine and catalpol on platelet aggregation of rabbits in vitro (X ±+ SD, n=6)

Dose (ug/ml)	Aggregation (%)	Inhibited Aggregation (%)
0	43.2 <u>+</u> 2.1	Not Applicable
40	36.1 <u>+</u> 6.2	20.1 <u>+</u> 13.5
80	32.6 <u>+</u> 5.6*	26.3 <u>+</u> 12.8
100	20.1 <u>+</u> 4.2**	51.2 <u>+</u> 10.2
160	15.2 <u>+</u> 5.2**	66.4 <u>+</u> 12.8
200	7.6 <u>+</u> 3.6***	85.6 <u>+</u> 9.6

^{*}p<0.05

FIG. 17

^{**}p<0.02

^{***}p<0.001

^{**}p<0.01

^{***}p<0.001

Table 8: Changes of plasma sugar, cholesterol, lipoprotein and apolipoprotein of the participated groups

groups			
Items	Treatment (n=60)	Control (n=40)	Normal (n=40)
FPG (mmol/l)			
Before treatment	13.4 <u>+</u> 3.67	12.98 <u>+</u> 3.10	8.95 <u>+</u> 2.33
After treatment	6.10 <u>+</u> 2.10**	8.90 <u>+</u> 2.70	8.77 <u>+</u> 3.21
TC (mmol/l)			
Before treatment	5.99 <u>+</u> 0.73	5.71 <u>+</u> 0.64	5.61 <u>+</u> 0.27
After treatment	4.23 <u>+</u> 0.51**	5.62 <u>+</u> 0.35	5.59 <u>+</u> 0.42
TG (mmol/l)			
Before treatment	2.67 <u>+</u> 0.38	2.25 <u>+</u> 0.31	2.27 <u>+</u> 0.48
After treatment	1.02 <u>+</u> 0.31**	2.24 <u>+</u> 0.47	1.57 <u>+</u> 0.33
HDL-C (mmol/l)			
Before treatment	1.01 <u>+</u> 0.10	1.18 <u>+</u> 0.25	1.12 <u>+</u> 0.20
After treatment	2.10 <u>+</u> 0.22**	1.24 <u>+</u> 0.16	1.98 <u>+</u> 0.18
LDL-C (mmol/l)			
Before treatment	4.90 <u>+</u> 0.37	4.10 <u>+</u> 0.27	4.02 <u>+</u> 0.16
After treatment	3.02 <u>+</u> 0.28**	4.03 <u>+</u> 0.38	3.43 <u>+</u> 0.20
APO A1 (g/l)			
Before treatment	1.01+0.21	1.02 <u>+</u> 0.07	1.05 <u>+</u> 0.11
After treatment	1.32+0.12*	1.05 <u>+</u> 0.05	1.29 <u>+</u> 0.21*
APO B (g/l)			
Before treatment	1.02+0.25	1.08 <u>+</u> 0.36	0.99 <u>+</u> 0.24
After treatment	0.69+0.18*	1.01 <u>+</u> 0.27	0.67 <u>+</u> 0.36*

^{*}p<0.05

^{**}p<0.01

Table 9: Hematological properties of the treatment group and control group before and after treatment (X + SD)

treatment (X ± SD)		
Items examined	Treatment group (n=60)	Control group (n=40)
Whole blood viscosity		
(mPa-S)		
Before treatment	6.98 <u>+</u> 0.91	6.95 <u>+</u> 1.26
After treatment	4.10 <u>+</u> 0.69	6.68 <u>+</u> 1.10
Blood plasma viscosity		
(mPa-S)		
Before treatment	1.94 <u>+</u> 0.42	1.93 <u>+</u> 0.55
After treatment	1.37 <u>+</u> 0.35	1.89 <u>+</u> 0.35
Fibrinogen (g/l)		
Before treatment	4.20 <u>+</u> 1.07	4.19 <u>+</u> 1.31
After treatment	3.16 <u>+</u> 1.05	4.11 <u>+</u> 1.18
Hematocrit (%)		
Before treatment	49.28 <u>+</u> 7.25	49.20 <u>+</u> 7.39
After treatment	40.26 <u>+</u> 4.67	47.02 <u>+</u> 6.28